Nasus Pharma Ltd (NSRX) files insider report for CEO Brendan O'Grady

Rhea-AI Filing Summary

Nasus Pharma Ltd filed an insider report identifying Brendan P. O'Grady as both a director and an officer, with the officer title of Chief Executive Officer. The report does not list him as a ten percent owner and shows no insider share transactions in this filing.

Key Terms

Chief Executive Officer, ten percent owner, reporting person

3 terms

Chief Executive Officer financial

"officer_title": "Chief Executive Officer""

A chief executive officer (CEO) is the top leader of a company, responsible for making major decisions, setting goals, and guiding the organization’s overall direction. Think of the CEO as the captain of a ship, steering it toward success. Investors pay close attention to the CEO because their leadership and strategy can significantly influence the company's performance and future growth.

ten percent owner regulatory

"is_ten_percent_owner": 0"

reporting person regulatory

"reportingPersons": [ { "name": "O'Grady Brendan P."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/31/2026 - 04:26 PM Accepted by SEC EDGAR 07/31/2026 - 04:25 PM Learn about SEC filing dates

FAQ

What does Nasus Pharma (NSRX) disclose about Brendan P. O'Grady in this insider filing?

The filing identifies Brendan P. O'Grady as both a director and an officer of Nasus Pharma Ltd, with the officer title of Chief Executive Officer. It is an insider report and includes no reported share transactions.

Does the NSRX insider filing show any share transactions by Brendan P. O'Grady?

No, the insider data report shows no buy, sell, exercise, gift, or other share transactions for Brendan P. O'Grady. All transaction counters, including buyCount, sellCount, and exerciseCount, are reported as zero in this filing.

Is Brendan P. O'Grady reported as a ten percent owner of Nasus Pharma (NSRX)?

No, Brendan P. O'Grady is not reported as a ten percent owner of Nasus Pharma Ltd. The insider data explicitly marks his ten percent owner status as 0, while confirming his roles as director and Chief Executive Officer.

What official role does Brendan P. O'Grady hold at Nasus Pharma (NSRX)?

Brendan P. O'Grady is listed as an officer with the title Chief Executive Officer of Nasus Pharma Ltd. He is also reported as a director, reflecting his dual governance and management responsibilities within the company’s leadership structure.

Does the NSRX insider report list any derivative positions for Brendan P. O'Grady?

No, the report shows no derivative positions for Brendan P. O'Grady. The derivativeSummary is empty and derivativeTransactionCount is zero, indicating no options, warrants, or other derivatives are reported in this particular filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Grady Brendan P.

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/27/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Brendan O'Grady	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)